甘李藥業(603087.SH):甘精胰島素注射液獲哈薩克斯坦藥品註冊批件
格隆匯9月17日丨甘李藥業(603087.SH)公佈,近日,公司收到哈薩克斯坦衞生部核准簽發的甘精胰島素注射液註冊批件。
此次公司獲得哈薩克斯坦衞生部批准的甘精胰島素注射液(3ml:300IU)即屬於胰島素類似物產品,又稱基礎重組胰島素類似物,注射起效後作用時間可持續24小時,能長效、平穩地控制患者的血糖,每日只需注射一次。
目前,在哈薩克斯坦境內,甘精胰島素注射液的主要供貨商為賽諾菲。賽諾菲的甘精胰島素產品來得時2019年的全球銷售額為30.12億歐元(賽諾菲2019年年報)。截至2020年6月30日,公司在甘精胰島素研發項目上已累計投入約5.7億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.